3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

NCT00077181 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Relapsing Chronic Myelogenous Leukemia
Secondary Acute Myeloid Leukemia

Interventions

DRUG: cytarabine
DRUG: triapine
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)